Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Mu
14 hours ago
- #hematology
- #leukemia
- #tyrosine kinase inhibitor
- Study evaluates olverembatinib-based therapy in transformed CML-LBP and R/R Ph+ ALL patients.
- 75 patients (26 CML-LBP, 49 R/R Ph+ ALL) with median age 51 years were analyzed.
- 78% achieved complete remission/CR with incomplete hematologic recovery by 28 days.
- 2-year overall survival probability was 43%, median survival 18 months.
- Higher hemoglobin and receiving a transplant significantly improved survival.
- Therapy was well-tolerated and effective for both conditions.